{
    "clinical_study": {
        "@rank": "83821", 
        "arm_group": {
            "arm_group_label": "Ozurdex in diabetic macular edema", 
            "arm_group_type": "Experimental", 
            "description": "Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months"
        }, 
        "brief_summary": {
            "textblock": "This study is undertaken to determine the effect of intravitreal long acting dexamethasone\n      implant,(Ozurdex\u00ae)in patients with diabetic macular edema.Diabetic macular edema is\n      important cause of visual impairment in patients with diabetes mellitus. Focal/ grid laser\n      photocoagulation is the standard of care in its management. Several adjuncts including\n      intravitreal corticosteroids, Pegabtanib Sodium ,Ranibizumab, Bevacizumab, non-steroidal\n      anti-inflammatory agents, corticosteroids, laser photocoagulation have been tried.\n      Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been shown to\n      reduce the retinal thickness and improve the visual acuity. However, recurrence of macular\n      edema in patients who receive intravitreal TA is a major concern as the patients need\n      multiple repeat injections because of its short half life.  A more potent steroid,\n      dexamethasone has also been tried as an alternative to TA for macular edema; however, its\n      short half life of only 3 hours prevents its clinical application. In search for the ideal\n      corticosteroid preparation, a Dexamethasone Posterior Segment Drug Delivery System\n      (Dexamethasone DDS - Ozurdex\u00ae, Allergan Inc, Irvine, California) was recently developed.\n      Promising results have been shown in certain patients with retinal vein occlusions, uveitis\n      receiving this intravitreal drug delivery system with improvement in visual acuity. The\n      present study introduces a novel concept of using Ozurdex \u00ae implant in patients with\n      diabetic macular edema."
        }, 
        "brief_title": "Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema", 
        "completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetic Macular Edema", 
            "Macular Edema, Cystoid", 
            "Vision Disorders", 
            "Clinically Significant Macular Edema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Vision Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is undertaken to determine the effect of intravitreal long acting dexamethasone\n      implant,(Ozurdex\u00ae)in patients with diabetic macular edema.Diabetic macular edema is\n      important cause of visual impairment in patients with diabetes mellitus. Focal/ grid laser\n      photocoagulation is the standard of care in its management. Several adjuncts including\n      intravitreal corticosteroids, Pegabtanib Sodium ,Ranibizumab, Bevacizumab, non-steroidal\n      anti-inflammatory agents, corticosteroids, laser photocoagulation have been tried.\n      Intravitreal Triamcinolone Acetonide (TA), a water insoluble steroid, has been shown to\n      reduce the retinal thickness and improve the visual acuity. However, recurrence of macular\n      edema in patients who receive intravitreal TA is a major concern as the patients need\n      multiple repeat injections because of its short half life. A more potent steroid,\n      dexamethasone has also been tried as an alternative to TA for macular edema; however, its\n      short half life of only 3 hours prevents its clinical application. In search for the ideal\n      corticosteroid preparation, a Dexamethasone Posterior Segment Drug Delivery System\n      (Dexamethasone DDS - Ozurdex\u00ae, Allergan Inc, Irvine, California) was recently developed.\n      Promising results have been shown in certain patients with retinal vein occlusions, uveitis\n      receiving this intravitreal drug delivery system with improvement in visual acuity. The\n      present study introduces a novel concept of using Ozurdex \u00ae implant in patients with\n      diabetic macular edema."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patients of Type 1 or Type 2 Diabetes Mellitus fulfilling the following inclusion\n             criteria shall be enrolled in the study:\n\n               1. Patients of Non Proliferative Diabetic retinopathy (NPDR)with clinicaly\n                  significant macular edema(CSME)\n\n               2. Patients with Proliferative Diabetic Retinopathy (PDR) with CSME where\n                  proliferative component has been adequately treated with laser photocoagulation\n\n               3. Diabetic patients withcystoid macular edema\n\n               4. Minimum central thickness on OCT not less than 300 microns\n\n        Exclusion Criteria:\n\n          1. Patients with history of ocular hypertension or glaucoma\n\n          2. Patients with media haze or pupillary non-dilation that does not allow good fundus\n             photography, FFA and OCT.\n\n          3. Patients with macular ischemia on FFA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "72 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698749", 
            "org_study_id": "PoojaBansal 13"
        }, 
        "intervention": {
            "arm_group_label": "Ozurdex in diabetic macular edema", 
            "description": "Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months", 
            "intervention_name": "long acting intravitreal dexamethasone implant", 
            "intervention_type": "Drug", 
            "other_name": "Ozurdex"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ozurdex", 
            "Diabetic macular edema", 
            "Central macular thickness"
        ], 
        "lastchanged_date": "September 29, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chandigarh", 
                    "country": "India", 
                    "zip": "160012"
                }, 
                "name": "Pooja Bansal"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema", 
        "overall_official": [
            {
                "affiliation": "Postgraduate Institute of Medical Education and Research", 
                "last_name": "POOJA BANSAL, MBBS,MS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Postgraduate Institute of Medical Education and Research", 
                "last_name": "VISHALI R GUPTA, MBBS,MS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Postgraduate Institute of Medical Education and Research", 
                "last_name": "AMOD GUPTA, MBBS,MS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is the change in the central macular thickness, either an increase or decrease, as measured by optical coherence tomography as compared to baseline central macular thickness", 
            "measure": "change in central macular thickness", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698749"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Postgraduate Institute of Medical Education and Research", 
            "investigator_full_name": "Pooja Bansal,MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in the visual acuity as measured by the logMAR visual acuity chart", 
            "measure": "Change in the visual acuity", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 months"
        }, 
        "source": "Postgraduate Institute of Medical Education and Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Postgraduate Institute of Medical Education and Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}